Analyst Reco. DiaSorin S.p.A.

Equities

DIA

IT0003492391

Medical Equipment, Supplies & Distribution

Market Closed - Borsa Italiana Other stock markets 16:45:00 18/06/2025 BST			5-day change	1st Jan Change
93.58 ^EUR	0.00%		-1.60%	-6.01%

06-17	DIARY - Italy to July 31	RE
06-10	DIARY - Italy to July 31	RE

Analyst Reco.

DIASORIN : Slight Q1 beat with 2025 guidance remaining unchanged	05-07
Kepler Cheuvreux Upgrades DiaSorin to Hold, Boosts PT	04-10	MT
DIASORIN : Slight Q4 miss but the 2025 outlook was encouraging	03-17
Deutsche Bank Begins Diasorin's Coverage at Buy	02-11	MT
Morgan Stanley Upgrades Diasorin to Equalweight, Boosts PT	11-07	MT
DIASORIN : In line Q3; higher end of the full-year guidance now targeted	11-06
DIASORIN : Q2 profitability beat; lower end of guidance upgraded	30/07/24
DIASORIN : Markets hailed the Q1 beat; guidance re-affirmed	13/05/24
DIASORIN : Profitability guidance miss; dreams inching towards reality	18/03/24
DIASORIN : Incorporating some caution	05/02/24
DIASORIN : Q3 profitability miss; Immunodiagnostics momentum continues; guidance unchanged	06/11/23
Chinese headwinds could be more severe than expected	22/09/23
DIASORIN : Taking on board the near-term difficulties	16/08/23
DIASORIN : Despite a soft Q2, guidance was unchanged	28/07/23
DIASORIN : Incorporating medium-term hiccups; but re-rating potential remains intact	19/05/23
DIASORIN : Mixed Q1; guidance unchanged	10/05/23
DIASORIN : Soft 2022 (end) + disappointing guidance; patience warranted	28/03/23
DIASORIN : A decent Q3 + better guidance but markets were spooked	28/10/22
DIASORIN : Healthy Q2 and H1; resulting in consecutive guidance upgrade	04/08/22
DIASORIN : Strong Q1 prompts guidance upgrade	10/05/22
DIASORIN : Healthy 2021 performance; 2022 guidance being reiterated	20/03/22
DIASORIN : Mid-to-long-term ambitions overshadowed by near-term headwinds	20/12/21
DIASORIN : Healthy performance led guidance upgrade	12/11/21
DIASORIN : Like peers, DiaSorin also turns cautious with its full-year targets	02/08/21
DIASORIN : Strong Q1; wide full-year guidance	17/05/21

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

DIASORIN : Slight Q1 beat with 2025 guidance remaining unchanged

May 07, 2025 at 10:04 pm